Proprietary Bio‑3D Printer (Kenzan)Owning a differentiated scaffold-free bioprinting platform (Bio-3D/Kenzan) is a durable competitive advantage. A unique assembly method for multicellular spheroids can create high switching costs for customers, enable platform licensing, and support long-term R&D and therapeutic pipelines.

Focus On Regenerative Medicine & Tissue EngineeringA clear strategic focus on regenerative medicine and tissue engineering aligns the company with a structurally growing specialty area. Dedicated niche positioning supports deep technical expertise, targeted partnerships, and product-platform development that remain relevant across multi-year clinical and commercialization cycles.

Strong Liquidity And Moderate LeverageA high equity ratio and manageable leverage provide financial resilience. Significant cash balances and moderate debt reduce short-term refinancing risk, support ongoing R&D and clinical programs, and give management flexibility to pursue partnerships or capital-efficient growth over the coming months.

Bears Say

Negative Operating And Free Cash FlowPersistent negative operating and free cash flows indicate the business is not converting operations into sustainable cash. Over 2–6 months this pressures liquidity, forces reliance on external funding, and constrains investment in trials, manufacturing scale-up, or commercialization activities necessary for long-term value creation.

Declining Revenue And MarginsMaterial declines in revenue and gross margin signal weakening core economics and potential competitive or operational issues. Sustained margin erosion and negative net margins undermine reinvestment capacity, reduce ability to scale commercial operations, and raise the bar for achieving profitable, self-sustaining growth.

Eroding Stockholders' EquityA multi-year decline in shareholders' equity reduces the capital buffer against adverse shocks and limits strategic flexibility. Over the medium term this can increase dilution risk from needed capital raises, tighten credit terms, and constrain the company's ability to fund clinical development or commercial expansion without external support.

4892 FAQ

What was Cyfuse Biomedical K.K.’s price range in the past 12 months?

Cyfuse Biomedical K.K. lowest stock price was ¥516.00 and its highest was ¥1412.00 in the past 12 months.

What is Cyfuse Biomedical K.K.’s market cap?

Cyfuse Biomedical K.K.’s market cap is ¥6.40B.

When is Cyfuse Biomedical K.K.’s upcoming earnings report date?

Cyfuse Biomedical K.K.’s upcoming earnings report date is May 20, 2026 which is in 93 days.

How were Cyfuse Biomedical K.K.’s earnings last quarter?

Cyfuse Biomedical K.K. released its earnings results on Feb 13, 2026. The company reported -¥12.09 earnings per share for the quarter, missing the consensus estimate of N/A by -¥12.09.

Is Cyfuse Biomedical K.K. overvalued?

According to Wall Street analysts Cyfuse Biomedical K.K.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cyfuse Biomedical K.K. pay dividends?

Cyfuse Biomedical K.K. does not currently pay dividends.

What is Cyfuse Biomedical K.K.’s EPS estimate?

Cyfuse Biomedical K.K.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cyfuse Biomedical K.K. have?

Cyfuse Biomedical K.K. has 9,963,900 shares outstanding.

What happened to Cyfuse Biomedical K.K.’s price movement after its last earnings report?

Cyfuse Biomedical K.K. reported an EPS of -¥12.09 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.277%.

Which hedge fund is a major shareholder of Cyfuse Biomedical K.K.?

Currently, no hedge funds are holding shares in JP:4892

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cyfuse Biomedical K.K.

Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine products in Japan. It develops cellular products in the field of regenerative therapy; and undertakes contract for cellular products for research and development. The company also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from cells. Cyfuse Biomedical K.K. was incorporated in 2010 and is based in Tokyo, Japan.